The worldwide increase in serious infections caused by multidrug-resistant (MDR) K. pneumoniae emphasizes the urgent need of new therapeutic strategies for the control of this pathogen. There is growing interest in the use of bacteriophages (or phages) to treat K. pneumoniae infections, and newly isolated phages are needed. Here, we report the isolation and physical/biological/molecular characterization of a novel lytic phage and its efficacy in the control of MDR K. pneumoniae. The phage vB_KpnS_Uniso31, referred to hereafter as phage Kpn31, was isolated from hospital wastewater using K. pneumoniae CCCD-K001 as the host. Phage Kpn31 presents a siphovirus-like morphotype and was classified as Demerecviridae; Sugarlandvirus based on its complete genome sequence. The 113,444 bp Kpn31 genome does not encode known toxins or antimicrobial resistance genes, nor does it encode depolymerases related sequences. Phage Kpn31 showed an eclipse time of 15 min and a burst size of 9.12 PFU/host cell, allowing us to conclude it replicates well in K. pneumoniae CCCD-K001 with a latency period of 30 min. Phage Kpn31 was shown to be effective against at least six MDR K. pneumoniae clinical isolates in in vitro antibacterial activity assays. Based on its features, phage Kpn31 has potential for controlling infections caused by MDR K. pneumoniae.
Aim: Two lytic phages were isolated using P. aeruginosa DSM19880 as host and fully characterized. Materials & methods: Phages were characterized physicochemically, biologically and genomically. Res...
E. coli is one of the etiological agents responsible for pyometra in female dogs, with conventional treatment involving ovariohysterectomy. Here, we report the isolation and full characterization of two novel lytic phages, viz. vB_EcoM_Uniso11 (ph0011) and vB_EcoM_Uniso21 (ph0021). Both phages belong to the order Caudovirales and present myovirus-like morphotypes, with phage ph0011 being classified as Myoviridae genus Asteriusvirus and phage ph0021 being classified as Myoviridae genus Tequatrovirus, based on their complete genome sequences. The 348,288 bp phage ph0011 and 165,222 bp phage ph0021 genomes do not encode toxins, integrases or antimicrobial resistance genes neither depolymerases related sequences. Both phages were shown to be effective against at least twelve E. coli clinical isolates in in vitro antibacterial activity assays. Based on their features, both phages have potential for controlling pyometra infections caused by E. coli. Phage ph0011 (reduction of 4.24 log CFU/mL) was more effective than phage ph0021 (reduction of 1.90 log CFU/mL) after 12 h of incubation at MOI 1000. As a cocktail, the two phages were highly effective in reducing the bacterial load (reduction of 5.57 log CFU/mL) at MOI 100, after 12 h of treatment. Both phages were structurally and functionally stabilized in vaginal egg formulations.
1 January 2026 in International Journal of Microbiology
Objectives: We are aimed at evaluating whether the widespread use of azithromycin during the COVID‐19 pandemic led to a significant increase in bacterial resistance compared with the prepandemic period and estimating the magnitude of this effect through a systematic review and meta‐analysis. Methods: This systematic review followed the PRISMA 2020 guidelines and Cochrane Handbook (Page,2021). Observational studies published between 2015 and 2025 reporting azithromycin resistance before and after the COVID‐19 pandemic were identified. Odds ratios (ORs) were pooled using a random‐effects model. Methodological quality was assessed using the Newcastle–Ottawa scale. Results: Eight studies met the eligibility criteria and were included in the quantitative synthesis. The meta‐analysis demonstrated a significant increase in azithromycin resistance in the postpandemic period, with a pooled OR of 2.71 (95% CI: 2.04–3.59). Substantial heterogeneity was observed ( I2 = 73.5 % ), justifying the use of a random‐effects model. Conclusions: The findings provide robust evidence that the excessive and largely empirical use of azithromycin during the COVID‐19 pandemic contributed to a global rise in bacterial resistance. Strengthening antimicrobial stewardship policies is essential to preserve the clinical effectiveness of macrolides during future public health emergencies.
27 July 2023 in The Journal of Infection in Developing Countries
Introduction: With the advent of the pandemic in 2020 and the lack of perspectives on the treatment of COVID-19, numerous therapeutic proposals have emerged, including hydroxychloroquine and azithromycin. Therefore, some studies have shown that in many countries, the demand for azithromycin has increased during the pandemic. In Brazil, antibiotics can only be purchased with a medical, dental, or veterinary prescription. This study aimed to determine whether the number of prescriptions made by veterinarians (which could be used by humans) has increased during the pandemic. Methodology: Data on the purchase of antibiotics made under veterinary prescriptions in Brazilian pharmacies between 2014 and 2021 were collected. To assess the changes in monthly trends in the use of the selected antibiotics, we applied the Joinpoint regression. Results: The most prescribed antibiotic in all years was cephalexin (35%), followed by amoxicillin (24%). During the pandemic, sales of azithromycin substantially increased. Regression analysis showed that since 2014, azithromycin prescriptions grew by an average of 0.67% per month. At the beginning of the pandemic, the monthly growth rate became 12.64%. When comparing azithromycin sales during the pandemic with the historical average (2014–2019), the increase was 41%. Conclusions: During the pandemic, there was no animal health situation in Brazil that required the use of this antibiotic. Veterinary prescriptions may have been an instrument for human access to azithromycin for the treatment of COVID-19. Stricter enforcement policies are needed to address this problem to avoid antimicrobial resistance.
Antimicrobial resistance (AMR) is a major One Health challenge, and Brazilian data integrating veterinary prescribing with local susceptibility profiles remain scarce. This study characterized antimicrobial prescribing by veterinarians and descriptively compared prescribing patterns with regional laboratory-reported resistance profiles in urinary and otic infections in dogs and cats. Questionnaire responses from 109 veterinarians and 1050 bacterial isolates (608 urinary/genitourinary and 442 otic; 18,137 susceptibility results in the source dataset before interpretive exclusions) were analyzed. Only 34/109 (31.2%) veterinarians requested antimicrobial susceptibility testing before therapy, more often specialists than general practitioners (43.2% vs. 23.1%; p = 0.035). General practitioners reported greater use of amoxicillin/clavulanate, enrofloxacin, doxycycline, and amoxicillin/ampicillin (p < 0.05). Higher overall prescribing intensity was associated with more frequent use of doxycycline, neomycin/tobramycin, cefalotin/cephalexin/cefazolin, and macrolides (p ≤ 0.04). Escherichia coli was reported as predominant in urinary samples, and Staphylococcus was reported in otic samples at genus level. Enrofloxacin showed relevant resistance among the main isolates, whereas amoxicillin/clavulanate reported resistance varied by bacterial species (71.4% resistance in Klebsiella pneumoniae and 8.9% in otic S. pseudintermedius). Treatment duration varied widely, particularly for otitis and urinary tract infections. The unlinked datasets identified potential areas for review, including opportunities to expand microbiological diagnostics, reduce empirical use of antimicrobials with relevant resistance, and standardize antimicrobial selection and treatment duration.